ITUS (ITUS)’s director Richard Williams Unloaded 25,000 Shares of the Company; Flaherty & Crumrine Total Return Fund (FLC) Sentiment Is 1.63

ITUS Corporation (NASDAQ:ITUS) Logo

Sentiment for Flaherty & Crumrine Total Return Fund Inc (FLC)

Flaherty & Crumrine Total Return Fund Inc (FLC) investors sentiment increased to 1.63 in Q4 2017. It’s up 0.73, from 0.9 in 2017Q3. The ratio is better, as 13 funds started new or increased stock positions, while 8 cut down and sold their stock positions in Flaherty & Crumrine Total Return Fund Inc. The funds in our database now own: 1.13 million shares, up from 1.05 million shares in 2017Q3. Also, the number of funds holding Flaherty & Crumrine Total Return Fund Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 4 Increased: 7 New Position: 6.

Rocky Mountain Advisers Llc holds 0.17% of its portfolio in Flaherty & Crumrine Total Return Fund Inc. for 2,000 shares. Capital Investment Advisors Llc owns 13,987 shares or 0.02% of their US portfolio. Moreover, Lpl Financial Llc has 0.01% invested in the company for 94,349 shares. The Missouri-based Moneta Group Investment Advisors Llc has invested 0.01% in the stock. Sit Investment Associates Inc, a Minnesota-based fund reported 10,000 shares.

It closed at $19.66 lastly. It is down 5.87% since April 12, 2017 and is downtrending. It has underperformed by 17.42% the S&P500.

The stock decreased 3.28% or $0.15 during the last trading session, reaching $4.43. About 202,751 shares traded. ITUS Corporation (NASDAQ:ITUS) has risen 11.12% since April 12, 2017 and is uptrending. It has underperformed by 0.43% the S&P500.

ITUS Corporation develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $73.68 million. The firm develops Cchek, a platform for non-invasive blood tests for the early detection of various cancers, including breast, lung, colon, melanoma, ovarian, liver, thyroid, pancreatic, appendiceal, uterine, osteosarcoma, leiomyosarcoma, liposarcoma, vulvar, and prostate cancer. It currently has negative earnings. It also develops immuno-therapy drugs for the treatment of cancer.

Richard Williams, director of Itus Corp, in an insider legal trade made a sale of 25,000 shares whose worth is estimated to be $116,000 at average stock price of $4.6. Richard Williams currently owns 25,000 shares or 0.15% of Itus Corp’s market cap.